ACTU Stock Forecast & Price Target

Actuate Therapeutics is supported by a lead asset, elraglusib, that has shown meaningful activity across difficult-to-treat cancers, including 53% clinical responses or disease control in heavily pretreated pediatric patients and a stronger mPDAC survival signal in the higher-exposure subgroup (HR 0.48, p<0.001). The company’s positive outlook is further reinforced by FDA clearance for a Phase 1/2 oral elraglusib study planned for 2H26, with PK/exposure data and a potential RP2D expected in 2H27, plus the prospect that 1–2 daily tablets could achieve target exposure with >95% oral bioavailability. Additional upside comes from pediatric neuroblastoma and CNS programs, potential rare pediatric disease PRV value of approximately $150M to $200M, and the cited rNPV of $656M versus net cash of $13.1M.

Actuate Therapeutics is facing a weak fundamental profile because it generated no revenues in both 1Q26 and 2Q26 while still posting net losses of $0.24 and $0.20 per diluted share, respectively, underscoring the absence of any commercial offset to operating expenses. Cash and cash equivalents fell from $8.1M at the end of 1Q26 to $4.44M at the end of 2Q26, and management indicated that this balance is not sufficient to fund operations beyond September 2026. With 2026 still projected to produce no revenues and a net loss of $0.61 per diluted share, the company remains highly dependent on external financing amid ongoing clinical-stage execution risk.